Emerging mechanisms of immunotherapy resistance in sarcomas.
Ontology highlight
ABSTRACT: Sarcomas are a heterogeneous group of over 150 mesenchymal neoplasms of bone and soft tissue. Clinical prognosis remains poor in the metastatic and refractory setting, despite treatment with traditional chemotherapies. A subset of sarcoma patients can exhibit remarkable responses to novel immune therapies; however, most patients will not respond. Emerging data from genetic and transcriptomic datasets suggests that patients who are resistant to checkpoint inhibitor monotherapy may have low expression of immune-related genes, suggesting that the sarcoma was not sufficiently immunogenic to trigger or maintain an immune response to generate tumor-specific immune effector cells. In this review, we discuss the emerging data surrounding potential mechanisms of resistance, including various biomar
SUBMITTER: Florou V
PROVIDER: S-EPMC8992586 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA